Treatment Practices for Extended-Stage Small Cell Lung Cancer

Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Real-world data may support a new way to consider follow-up treatment for patients who are older with extensive-stage small cell lung cancer.

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

Tislelizumab plus chemotherapy demonstrated superior OS, PFS, ORR, and DOR results compared with placebo plus chemotherapy in first-line ES-SCLC.

Intravenous olvi-vec demonstrated a manageable safety and tolerability profile consistent with previous trials evaluating the investigational agent.